A research study focused on magic mushrooms in Canada revealed that nearly 80% of participants are of the view that psilocybin, a substance found in these mushrooms, should be permitted for medical treatment to aid patients in distress. Additionally, roughly two-thirds of Canadian participants within the same study concurred that this substance should be legally permissible for those in need.
Beyond simply making psilocybin more accessible, a striking 84.8 percent of participants expressed the belief that the costs of such treatments should be covered by the public health system. A significant portion of Canadians see psilocybin as a practical solution, particularly in treating end-of-life distress.
[toc]
Key Insights:
- Citizens of Québec, Ontario, Alberta, and British Columbia view psilocybin as a legitimate medical option for managing end-of-life existential distress.
- Magic mushrooms are deemed safe for use in treating existential distress.
- Participants in two double-blind trials experienced immediate and long-lasting benefits, with effects persisting for six months or even more.
Understanding Existential Distress
Existential distress, akin to existential suffering, spiritual distress, and demoralization, arises when individuals face their own mortality. Such patients may grapple with feelings of helplessness, isolation, anxiety, and a loss of purpose and meaning. This form of distress is particularly prevalent among patients with life-threatening illnesses, possibly leading to a hastened desire for death or thoughts of suicide.
Generally, individuals dealing with terminal diseases or significant life changes are most likely to experience this type of distress. It can significantly impact their mental health and overall quality of life.
Existential therapy aims to address issues such as anxiety, depression, grief, loneliness, apathy, despair, identity confusion, and feelings of purposelessness and existential fear. This therapy can necessitate numerous sessions and may not work for everyone.
The ambiguity regarding the effectiveness of such therapy is a key factor driving many individuals to explore alternative treatments.
Health Canada’s Standpoint on Psilocybin for Medical Treatment
Over the last two decades, preliminary clinical trials have emphasized the possible advantages of psychedelic substances in addressing complex mental disorders. Specifically, Psilocybin has been found to rapidly and permanently reduce existential distress in patients approaching the end of their lives.
Recognizing the potential efficacy of these proposed hallucinogenic mushrooms, especially when conventional treatments are insufficient, Health Canada revised the Special Access Program in 2022. This revision permits healthcare professionals to request controlled substances for their patients.
Canadian Advocacy for Psilocybin Accessibility
A study published in the Palliative Care Journal evaluates societal views on psilocybin-assisted therapy for end-of-life care. The data from the study includes:
| Methodology | Participation from 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia. 19% of whom had previously used psilocybin (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% consider psilocybin-assisted therapy a legitimate medical option for treating end-of-life existential distress. 63.3% believe psilocybin should be integrated into medical treatment. 84.8% support the provision of this therapy by the public health system. 44.2% think healthcare professionals should administer the substance without Health Canada’s supervision. |
The outcomes align with surveys from Canada, England, and Australia. The researchers highlighted that their study is distinctive as it focuses on the use of psychoactive substances to address existential distress in end-of-life situations.
Why Canadians Endorse Psilocybin Usage
An increasing number of Canadians are supporting the use of psilocybin for treatment, mainly due to findings from esteemed research institutions. Another factor is the perceived safety of psilocybin mushrooms for easing existential distress. In various studies, subjects have not reported severe adverse health effects, such as multi-organ failure.
| Study | Approach | Outcomes |
| Johns Hopkins Study | 51 patients were given a high dose of psilocybin and a low dose as an active placebo control | Immediate and enduring The benefits of this therapy can last up to six months or more. Its efficacy is largely due to mystical experiences which often involve a profound sense of unity and deep emotional insights. |
| New York University Trial | A random selection of 29 patients was assigned to either receive psilocybin or the active placebo niacin. | The results were in line with those from the Johns Hopkins study. Participants who were administered psilocybin reported psychological relief and a more positive outlook on life and death. |
| BMC Palliative Care | A study was conducted on nineteen participants, which included 7 doctors, 4 active nurses, 4 chaplains, 3 social workers, and a psychologist. The objective was to ascertain the viewpoint of palliative care professionals on existential distress and their perspective on psychedelic therapy as a treatment. | As per the practitioners of palliative care, there is potential in psychedelic-assisted therapy (PAT) to alleviate existential distress. |
Patient Experiences
Scientific research isn’t the only source of evidence supporting the effectiveness of psilocybin. Numerous patient testimonials further highlight its potential to improve mental health and overall quality of life.
Yokoi’s Experience
Mio Yokoi, a patient with terminal stage 4 pancreatic cancer, shares her enlightening experience during her assisted therapy. She recalls envisioning herself on a raft, surrounded by nature, and in the company of imaginary creatures. This vision gave her a profound sense of the universe’s interconnectedness and support, bringing her immense peace and affirmation.
Despite availing traditional mental health support, Yokoi still struggled with severe anxiety and distress following her diagnosis. Psilocybin therapy aided her in reconnecting with her body and provided a tangible sense of love and support. This has significantly improved her emotional and mental health.
The Story of Chrissy
Chrissy, a woman in her 50s, was battling stage 4 breast cancer that had metastasized to her lungs. She was working full-time as an administrative supervisor in healthcare when she participated in the study and identified as an atheist. She was diagnosed with Generalized Anxiety Disorder during her screening.
Chrissy experienced significant decreases in her anxiety, depression, fear of death, hopelessness, and demoralization levels. When asked about any changes in her religious or spiritual beliefs post her therapy session, she expressed that the experiences had added depth and reality to her beliefs.
Brenda’s Journey
During her therapy, Brenda underwent the sensation of death twice. These experiences led her to shed her fear of death and instead perceive it as a natural part of the life cycle. She credited the study for initiating her healing journey from childhood trauma. Her data reflected this profound change.
Her fear and anxiety about death reduced while her spirituality increased.
Availability of Magic Mushroom Products in Canada
At present, there might be limitations on the availability of psilocybin capsules and other products designed to alleviate existential distress or other mental health conditions. However, reliable online dispensaries can provide these products when needed.
| Attribute | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Originates from Brazil and some nearby South American countries. | Discovered in Cambodia, specifically around the Angkor Wat Temple. | Linked to Penis Envy mushrooms, which gained popularity in the 1970s. |
| Potency | Moderately potent; suitable for beginners. | Also moderately potent; perfect for those starting out. | Extremely potent; best for those with intermediate to advanced experience. |
| Effects | Triggers a mental buzz, slight disorientation, enhanced color perception, euphoria, spiritual experiences, increased creativity, and improved focus. | Induces an energizing and long-lasting high, minor visual distortions, increased creativity, euphoria, a smooth physical high, fractal images, and feelings of happiness. | Leads to deep shamanic experiences, vision quests, intense mystical experiences, heightened creativity, focus, social awareness, and mood enhancement. |
Using Psilocybin Products to Ease End-of-life Discomfort
The existential or end-of-life distress can significantly burden patients nearing the end of their lives. Traditional treatments often do not fully alleviate this distress, leading to an increase in Canadian support for greater accessibility to magic mushrooms in public healthcare. This growing public interest could
Advocate for regulatory authorities to acknowledge the potential of magic mushrooms as a feasible treatment option. Acquire your psychedelics and shroom delivery from Magic Mush Canada.
Frequently Asked Questions
What should patients expect from Psilocybin-Assisted Therapy?
Experiences with Psychedelic-assisted therapy (PAT) differ greatly among patients. It’s crucial to adhere to specific steps and prepare adequately to guarantee a positive outcome. Patients need to complete thorough screening and mental readiness exercises before ingesting the substance.
- Preparation before the Session: Patients undergo a thorough assessment. The therapist discusses the goals and expectations of the patient to set intentions for the session. The therapist also explains the effects of the process and what to expect during the session.
- The Session: In a serene, distraction-free environment, patients are given a regulated dose of the substance. This setting promotes relaxation and self-reflection. The therapist remains present, offering continuous support and guidance.
- Post-Session Integration Therapy: This therapy helps patients comprehend and process their experiences. Follow-up sessions provide ongoing support and counselling to reinforce the insights and changes acquired during therapy.
How does psilocybin affect the brains of distressed patients?
Psilocybin interacts with the brain by binding to serotonin receptors, primarily the 5-HT2A receptor. This interaction can lead to alterations in perception, mood, and cognition, resulting in substantial changes in consciousness, emotional breakthroughs, and new viewpoints.
Is psilocybin therapy available to everyone?
Not everyone is a suitable candidate for psilocybin therapy. Individuals with certain mental health conditions or existential distress are thoroughly screened to exclude those with a history of psychosis.
Related Articles:
